A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
Johnson & Johnson Private Limited
AstraZeneca
University of Maryland, Baltimore
Medical University of Vienna
Hoffmann-La Roche
GlaxoSmithKline
Tampere University Hospital
Sanofi